cloudfront

Report Detail

Pharmaceuticals & HealthcareNarcolepsy - Pipeline Review, H2 2018

  • RnM2474168
  • |
  • 9 October, 2018
  • |
  • Global
  • |
  • 88 pages
  • |
  • Global Markets Direct
  • |
  • Pharmaceuticals & Healthcare

Narcolepsy - Pipeline Review, H2 2018

Table of Contents

    List of Tables

      List of Figures

        Introduction

          Global Markets Direct Report Coverage

            Narcolepsy - Overview

              Narcolepsy - Therapeutics Development

                Pipeline Overview

                  Pipeline by Companies

                    Pipeline by Universities/Institutes

                      Products under Development by Companies

                        Products under Development by Universities/Institutes

                          Narcolepsy - Therapeutics Assessment

                            Assessment by Target

                              Assessment by Mechanism of Action

                                Assessment by Route of Administration

                                  Assessment by Molecule Type

                                    Narcolepsy - Companies Involved in Therapeutics Development

                                      Avadel Pharmaceuticals Plc

                                        Bioprojet SCR

                                          Evotec AG

                                            F. Hoffmann-La Roche Ltd

                                              H.A.C. Pharma

                                                Heptares Therapeutics Ltd

                                                  Jazz Pharmaceuticals Plc

                                                    Ono Pharmaceutical Co Ltd

                                                      OptiNose US Inc

                                                        SK Biopharmaceuticals Co Ltd

                                                          Taisho Pharmaceutical Holdings Co Ltd

                                                            Takeda Pharmaceutical Co Ltd

                                                              Theranexus SAS

                                                                Narcolepsy - Drug Profiles

                                                                  (flecainide acetate + modafinil) - Drug Profile

                                                                    Product Description

                                                                      Mechanism Of Action

                                                                        R&D Progress

                                                                          arbaclofen - Drug Profile

                                                                            Product Description

                                                                              Mechanism Of Action

                                                                                R&D Progress

                                                                                  JZP-258 - Drug Profile

                                                                                    Product Description

                                                                                      Mechanism Of Action

                                                                                        R&D Progress

                                                                                          JZP-386 - Drug Profile

                                                                                            Product Description

                                                                                              Mechanism Of Action

                                                                                                R&D Progress

                                                                                                  JZP-507 - Drug Profile

                                                                                                    Product Description

                                                                                                      Mechanism Of Action

                                                                                                        R&D Progress

                                                                                                          mazindol - Drug Profile

                                                                                                            Product Description

                                                                                                              Mechanism Of Action

                                                                                                                R&D Progress

                                                                                                                  mazindol - Drug Profile

                                                                                                                    Product Description

                                                                                                                      Mechanism Of Action

                                                                                                                        R&D Progress

                                                                                                                          ONO-4127 - Drug Profile

                                                                                                                            Product Description

                                                                                                                              Mechanism Of Action

                                                                                                                                R&D Progress

                                                                                                                                  OPN-021 - Drug Profile

                                                                                                                                    Product Description

                                                                                                                                      Mechanism Of Action

                                                                                                                                        R&D Progress

                                                                                                                                          pentylenetetrazol - Drug Profile

                                                                                                                                            Product Description

                                                                                                                                              Mechanism Of Action

                                                                                                                                                R&D Progress

                                                                                                                                                  pitolisant - Drug Profile

                                                                                                                                                    Product Description

                                                                                                                                                      Mechanism Of Action

                                                                                                                                                        R&D Progress

                                                                                                                                                          RO-5256390 - Drug Profile

                                                                                                                                                            Product Description

                                                                                                                                                              Mechanism Of Action

                                                                                                                                                                R&D Progress

                                                                                                                                                                  SLS-010 - Drug Profile

                                                                                                                                                                    Product Description

                                                                                                                                                                      Mechanism Of Action

                                                                                                                                                                        R&D Progress

                                                                                                                                                                          Small Molecule to Agonize Orexin Receptor 2 for Narcolepsy - Drug Profile

                                                                                                                                                                            Product Description

                                                                                                                                                                              Mechanism Of Action

                                                                                                                                                                                R&D Progress

                                                                                                                                                                                  Small Molecule to Agonize Orexin-2 for Narcolepsy and Sleep Disorders - Drug Profile

                                                                                                                                                                                    Product Description

                                                                                                                                                                                      Mechanism Of Action

                                                                                                                                                                                        R&D Progress

                                                                                                                                                                                          sodium oxybate - Drug Profile

                                                                                                                                                                                            Product Description

                                                                                                                                                                                              Mechanism Of Action

                                                                                                                                                                                                R&D Progress

                                                                                                                                                                                                  sodium oxybate ER - Drug Profile

                                                                                                                                                                                                    Product Description

                                                                                                                                                                                                      Mechanism Of Action

                                                                                                                                                                                                        R&D Progress

                                                                                                                                                                                                          solriamfetol hydrochloride - Drug Profile

                                                                                                                                                                                                            Product Description

                                                                                                                                                                                                              Mechanism Of Action

                                                                                                                                                                                                                R&D Progress

                                                                                                                                                                                                                  SUVNG-3031 - Drug Profile

                                                                                                                                                                                                                    Product Description

                                                                                                                                                                                                                      Mechanism Of Action

                                                                                                                                                                                                                        R&D Progress

                                                                                                                                                                                                                          TAK-925 - Drug Profile

                                                                                                                                                                                                                            Product Description

                                                                                                                                                                                                                              Mechanism Of Action

                                                                                                                                                                                                                                R&D Progress

                                                                                                                                                                                                                                  TS-091 - Drug Profile

                                                                                                                                                                                                                                    Product Description

                                                                                                                                                                                                                                      Mechanism Of Action

                                                                                                                                                                                                                                        R&D Progress

                                                                                                                                                                                                                                          XW-10172 - Drug Profile

                                                                                                                                                                                                                                            Product Description

                                                                                                                                                                                                                                              Mechanism Of Action

                                                                                                                                                                                                                                                R&D Progress

                                                                                                                                                                                                                                                  XW-10282 - Drug Profile

                                                                                                                                                                                                                                                    Product Description

                                                                                                                                                                                                                                                      Mechanism Of Action

                                                                                                                                                                                                                                                        R&D Progress

                                                                                                                                                                                                                                                          YNT-185 - Drug Profile

                                                                                                                                                                                                                                                            Product Description

                                                                                                                                                                                                                                                              Mechanism Of Action

                                                                                                                                                                                                                                                                R&D Progress

                                                                                                                                                                                                                                                                  Narcolepsy - Dormant Projects

                                                                                                                                                                                                                                                                    Narcolepsy - Discontinued Products

                                                                                                                                                                                                                                                                      Narcolepsy - Product Development Milestones

                                                                                                                                                                                                                                                                        Featured News & Press Releases

                                                                                                                                                                                                                                                                          Sep 10, 2018: XW Labs appoints clinical development veteran Dr. Daniel Canafax as Chief Medical Officer

                                                                                                                                                                                                                                                                            Sep 05, 2018: Harmony Biosciences to present data on its investigational product, Pitolisant, at upcoming International Narcolepsy Symposium

                                                                                                                                                                                                                                                                              Jun 27, 2018: Jazz Pharmaceuticals Announces FDA Acceptance of Supplemental New Drug Application for Xyrem (sodium oxybate) to Treat Cataplexy and Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients

                                                                                                                                                                                                                                                                                Jun 03, 2018: Jazz Pharmaceuticals Presents Long-Term Safety and Efficacy Data for Xyrem (sodium oxybate) in Pediatric Patients with Narcolepsy with Cataplexy

                                                                                                                                                                                                                                                                                  Jun 03, 2018: Jazz Pharmaceuticals Presents Long-Term Safety and Efficacy Data from Phase 3 TONES 5 Study of Solriamfetol for Excessive Sleepiness in Narcolepsy or Obstructive Sleep Apnea

                                                                                                                                                                                                                                                                                    Jun 01, 2018: Suven Life Sciences participating at Sleep 2018 at Baltimore, MD. USA

                                                                                                                                                                                                                                                                                      May 31, 2018: Harmony Biosciences to Present Data On Its Investigational Product, Pitolisant, At Upcoming SLEEP Annual Meeting

                                                                                                                                                                                                                                                                                        May 22, 2018: Bioprojet: Pitolisant Progresses Towards the U.S. Market

                                                                                                                                                                                                                                                                                          May 21, 2018: Harmony Biosciences Receives Breakthrough Therapy And Fast Track Designations For Pitolisant

                                                                                                                                                                                                                                                                                            May 10, 2018: Jazz Pharmaceuticals to Present Data on Sodium Oxybate at SLEEP 2018 Annual Meeting

                                                                                                                                                                                                                                                                                              May 10, 2018: Jazz Pharmaceuticals to Present Data on Solriamfetol at SLEEP 2018 Annual Meeting

                                                                                                                                                                                                                                                                                                May 01, 2018: Jazz Pharmaceuticals Submits Supplemental New Drug Application for Xyrem (sodium oxybate) to Treat Cataplexy and Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients

                                                                                                                                                                                                                                                                                                  Mar 22, 2018: AOP Orphan will distribute Wakix (pitolisant) from Bioprojet Pharma in Austria, Nordic countries and Central Eastern Europe

                                                                                                                                                                                                                                                                                                    Mar 12, 2018: XW Labs Initiates First-in-Human Phase I Study for Novel Narcolepsy Treatment

                                                                                                                                                                                                                                                                                                      Mar 02, 2018: Jazz Pharmaceuticals Announces FDA Acceptance of NDA for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea

                                                                                                                                                                                                                                                                                                        Appendix

                                                                                                                                                                                                                                                                                                          Methodology

                                                                                                                                                                                                                                                                                                            Coverage

                                                                                                                                                                                                                                                                                                              Secondary Research

                                                                                                                                                                                                                                                                                                                Primary Research

                                                                                                                                                                                                                                                                                                                  Expert Panel Validation

                                                                                                                                                                                                                                                                                                                    Contact Us

                                                                                                                                                                                                                                                                                                                      Disclaimer

                                                                                                                                                                                                                                                                                                                      Narcolepsy - Pipeline Review, H2 2018

                                                                                                                                                                                                                                                                                                                      Summary

                                                                                                                                                                                                                                                                                                                      Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Narcolepsy - Pipeline Review, H2 2018, provides an overview of the Narcolepsy (Central Nervous System) pipeline landscape.

                                                                                                                                                                                                                                                                                                                      Narcolepsy is a sleep disorder that causes excessive sleepiness and frequent daytime sleep attacks. Symptoms of narcolepsy include excessive daytime sleepiness (EDS), cataplexy, hallucinations and sleep paralysis. Narcolepsy treatment includes lifestyle change, medication and counseling.

                                                                                                                                                                                                                                                                                                                      Report Highlights

                                                                                                                                                                                                                                                                                                                      Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Narcolepsy - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Narcolepsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

                                                                                                                                                                                                                                                                                                                      The Narcolepsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Narcolepsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 4, 4, 4, 5, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

                                                                                                                                                                                                                                                                                                                      Narcolepsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

                                                                                                                                                                                                                                                                                                                      Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

                                                                                                                                                                                                                                                                                                                      Scope

                                                                                                                                                                                                                                                                                                                      - The pipeline guide provides a snapshot of the global therapeutic landscape of Narcolepsy (Central Nervous System).
                                                                                                                                                                                                                                                                                                                      - The pipeline guide reviews pipeline therapeutics for Narcolepsy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
                                                                                                                                                                                                                                                                                                                      - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
                                                                                                                                                                                                                                                                                                                      - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
                                                                                                                                                                                                                                                                                                                      - The pipeline guide reviews key companies involved in Narcolepsy (Central Nervous System) therapeutics and enlists all their major and minor projects.
                                                                                                                                                                                                                                                                                                                      - The pipeline guide evaluates Narcolepsy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
                                                                                                                                                                                                                                                                                                                      - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
                                                                                                                                                                                                                                                                                                                      - The pipeline guide reviews latest news related to pipeline therapeutics for Narcolepsy (Central Nervous System)

                                                                                                                                                                                                                                                                                                                      Reasons to buy

                                                                                                                                                                                                                                                                                                                      - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
                                                                                                                                                                                                                                                                                                                      - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
                                                                                                                                                                                                                                                                                                                      - Find and recognize significant and varied types of therapeutics under development for Narcolepsy (Central Nervous System).
                                                                                                                                                                                                                                                                                                                      - Classify potential new clients or partners in the target demographic.
                                                                                                                                                                                                                                                                                                                      - Develop tactical initiatives by understanding the focus areas of leading companies.
                                                                                                                                                                                                                                                                                                                      - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
                                                                                                                                                                                                                                                                                                                      - Formulate corrective measures for pipeline projects by understanding Narcolepsy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
                                                                                                                                                                                                                                                                                                                      - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
                                                                                                                                                                                                                                                                                                                      - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.




                                                                                                                                                                                                                                                                                                                      Summary:
                                                                                                                                                                                                                                                                                                                      Get latest Market Research Reports on Narcolepsy. Industry analysis & Market Report on Narcolepsy is a syndicated market report, published as Narcolepsy - Pipeline Review, H2 2018. It is complete Research Study and Industry Analysis of Narcolepsy market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.


                                                                                                                                                                                                                                                                                                                      REPORT YOU MIGHT BE INTERESTED

                                                                                                                                                                                                                                                                                                                      Purchase this Report

                                                                                                                                                                                                                                                                                                                      $2,000.00
                                                                                                                                                                                                                                                                                                                      $4,000.00
                                                                                                                                                                                                                                                                                                                      $6,000.00
                                                                                                                                                                                                                                                                                                                      1,343.00
                                                                                                                                                                                                                                                                                                                      2,686.00
                                                                                                                                                                                                                                                                                                                      4,029.00
                                                                                                                                                                                                                                                                                                                      1,840.40
                                                                                                                                                                                                                                                                                                                      3,680.80
                                                                                                                                                                                                                                                                                                                      5,521.20
                                                                                                                                                                                                                                                                                                                      242,280.00
                                                                                                                                                                                                                                                                                                                      484,560.00
                                                                                                                                                                                                                                                                                                                      726,840.00
                                                                                                                                                                                                                                                                                                                      132,626.80
                                                                                                                                                                                                                                                                                                                      265,253.60
                                                                                                                                                                                                                                                                                                                      397,880.40
                                                                                                                                                                                                                                                                                                                      Credit card Logo

                                                                                                                                                                                                                                                                                                                      Related Reports


                                                                                                                                                                                                                                                                                                                      Reason to Buy

                                                                                                                                                                                                                                                                                                                      Request for Sample of this report